Tiziana Life Sciences Ltd (NASDAQ:TLSA) was awarded a Buy rating with a $7 price target by BTIG, which pointed to the biotech's approach to modulating central nervous system inflammation as a potential leading treatment for neurodegenerative disease.

The clinical-stage company is developing foralumab, an anti-CD3 antibody delivered via nasal spray, to stimulate regulatory T-cell (Treg) production and reduce the inflammatory processes that drive neurodegeneration.

The nasal delivery targets NALT lymphoid tissue, and because NALT Tregs cross paths with the CNS lymphatic system, the stimulated Tregs are naturally primed to reduce inflammation from CNS antigens and reprogram overactive microglial cells, which are central to neurodegenerative disease.

BTIG noted that while definitive clinical data are still being developed, Tiziana has used TSPO imaging to demonstrate that foralumab reduces CNS inflammation in patients with secondary progressive MS (SPMS), multiple system atrophy (MSA) and Alzheimer's disease.

The analysts flagged SPMS and MSA as significant commercial opportunities given the unmet medical need in both indications: approved SPMS drugs are only effective early in the disease, soon after progression from relapsing remitting MS, while MSA currently has no approved disease-modifying treatments.

BTIG named the INFORM-MS trial, due at ACTRIMS/ECTRIMS in Toronto in October, as the stock's biggest near-term catalyst, one that could de-risk the whole pipeline if the TSPO imaging biomarker's reductions track with symptoms like fatigue. A positive result, per BTIG, would be a biomarker reduction in about 75% of patients despite the trial's short 12-week span. MSA data are still to come, with an Alzheimer's readout expected in the first half of 2027.

BTIG called the central thesis straightforward, pointing to the well-documented ability of Tregs to reduce inflammation in neuroscience and immunology research. While others have shown that NALT Tregs can be stimulated to combat neurodegeneration, the analysts noted foralumab is easier to deliver than cellular therapies.

The main open question, according to BTIG, is whether Tiziana's approach generates enough Tregs to drive clinical effects, though imaging data across SPMS, MSA and Alzheimer's suggest the approach is producing measurable immunomodulation.

Analysts also flagged foralumab as a strong combination candidate, since its nasal delivery reprograms the immune system toward tolerance rather than depleting or blocking immune cells, avoiding systemic T-cell activation and, so far, any serious adverse events across 37 patient years of exposure.